Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI’s Image of the Year
BEDFORD, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that an image generated using LNTH-2513 (18F-GP1) PET/CT was awarded SNMMI’s Image of the Year at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting in Los Angeles, California. The recognition was
BEDFORD, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that an image generated using LNTH-2513 (18F-GP1) PET/CT was awarded SNMMI’s Image of the Year at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting in Los Angeles, California. The recognition was presented in connection with investigator-initiated trial results evaluating LNTH-2513 PET/CT for the detection of acute lower-extremity deep vein thrombosis (DVT) in symptomatic patients.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.